Iowa 'driver shortage' bill backlash; Women in trucking; Science of Sales
On episode 820 of WHAT THE TRUCK?!? Dooner is talking about the a new bipartisan bill in Iowa that has the driving community up in arms. We'll take a look at why Iowa is trying to add even more drivers to an over capacity market and the damage the driver shortage myth does to our industry.
Mid-America Trucking Show 2025 may have come to an end but we'll recap the sights and sounds from America's biggest truck show.
Travelers' Elizabeth Simpkins talks about the tremendous progress made by women in trucking.
Trader Interactive's Charles Bowles shares the latest data on heavy duty truck buying demographics.Ben Tschirgi just founded his own company ScienceOfSales. After a decade of leading sales teams at companies like Cowan Logistics, Tschirgi is now helping other businesses use AI to scale their revenue.
Plus; Trevor Milton pardoned; squats across MATS; monkey truckers and more.
Catch new shows live at noon EDT Mondays, Wednesdays and Fridays on FreightWaves LinkedIn, Facebook, X or YouTube, or on demand by looking up WHAT THE TRUCK?!? on your favorite podcast player and at 5 p.m. Eastern on SiriusXM's Road Dog Trucking Channel 146.
Watch on YouTubeCheck out the WTT merch store
Visit our sponsor
Subscribe to the WTT newsletter
Apple Podcasts
Spotify
More FreightWaves Podcasts
The post Iowa 'driver shortage' bill backlash; Women in trucking; Science of Sales | WHAT THE TRUCK?!? appeared first on FreightWaves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.
Yahoo
an hour ago
- Yahoo
Atlas Announces Timing of Second Quarter 2025 Earnings Release and Conference Call
AUSTIN, Texas, June 10, 2025--(BUSINESS WIRE)--Atlas Energy Solutions Inc. (NYSE: AESI) ("Atlas" or the "Company") today announced that it will issue its second quarter 2025 earnings release after market close on Monday, August 4, 2025, and will host a conference call to discuss financial and operational results at 9:00am Central Time (10:00am Eastern Time) on Tuesday, August 5, 2025. A live webcast will be available at Please join the webcast at least 10 minutes ahead of the start time to ensure a proper connection and registration. An archived version of the second quarter 2025 earnings materials will be made available on the Company's website. About Atlas Energy Solutions Atlas Energy Solutions Inc. (NYSE: AESI) is a leading solutions provider to the energy industry. Atlas' portfolio of offerings includes oilfield logistics, distributed power systems, and the largest proppant supply network in the Permian Basin. With a focus on leveraging technology, automation, and remote operations to enhance efficiencies, Atlas is centered around a core mission of improving human beings' access to hydrocarbons that power our lives and, by doing so, maximizing value creation for our shareholders. View source version on Contacts Investor Contact Kyle Turlington5918 W Courtyard Drive, Suite #500Austin, Texas 78730United StatesT: 512-220-1200IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
